genedrive plc
("genedrive" or the "Company")
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that today David Budd, Chief Executive Officer, acquired 43,330 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 11.5p per share and Chris Yates, Non-Executive Director, acquired 25,000 Ordinary Shares at 11.56p per share.
Following these purchases, David Budd is interested in 188,710 Ordinary Shares, 0.5% of the issued share capital of the Company, and Chris Yates is interested in 41,304 Ordinary Shares, 0.1% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a. |
Name |
1. David Budd 2. Chris Yates |
2. |
Reason for the notification |
a. |
Position/status |
1. Chief Executive Officer 2. Non-Executive Director |
a. |
Initial notification /Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a. |
Name |
genedrive plc |
b. |
LEI |
213800ZYODIRZ87Y4K14 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary shares of 1.5 pence each GB00B1VKB244 |
b. |
Nature of the transaction |
Purchase |
c. |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
1. 11.50p 2. 11.56p |
1. 43,330 2. 25,000 |
|
d. |
Aggregated information · Aggregated volume · Price |
N/A |
e. |
Date of the transaction |
2020-02-04 |
f. |
Place of the transaction |
London Stock Exchange, AIM |
For further details please contact:
genedrive plc |
+44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+44 (0)20 7418 8900 |
James Steel / Oliver Jackson |
|
|
|
Stanford Capital Partners Limited (Joint Broker) |
+44 (0)20 3815 8880 |
Patrick Claridge / John Howes |
|
|
|
Walbrook PR Ltd (Media Relations & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |